Rpo LLC Fate Therapeutics Inc Transaction History

Rpo LLC

$68.8 Million
Q4 2024

A detailed history of Rpo LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Rpo LLC holds 14,222 shares of FATE stock, worth $14,648. This represents 0.03% of its overall portfolio holdings.

Number of Shares

14,222

Holding current value

$14,648

% of portfolio

0.03%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 12, 2025	BUY	$1.61 - $3.35 $22,897 - $47,643	14,222 New	14,222 $23,000
Q4 2023 Feb 12, 2024	BUY	$1.65 - $3.94 $20,306 - $48,489	12,307 New	12,307 $46,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

Redmile Group, LLC San Francisco, CA

12.9M
Shares

$13.3 Million
1.66% of portfolio
Vanguard Group Inc Valley Forge, PA

10.3M
Shares

$10.6 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$10.4 Million
0.0% of portfolio
Bellevue Group Ag Kuesnacht, V8

4.84M
Shares

$4.98 Million
0.16% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

4.38M
Shares

$4.51 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $99.9M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rpo LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rpo LLC with notifications on news.

Account